---
schema_version: "secwatch.filing_event.v1"
accession: "0000934549-24-000003"
form_type: "8-K"
ticker: "ACTG"
cik: "0000934549"
company_name: "ACACIA RESEARCH CORP"
filed_at: "2024-01-22T23:59:59+00:00"
generated_at: "2026-06-06T20:56:56.034445+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acacia Research sells entire Arix stake for $57.1M to RTW Biotech

## Summary
- Sold 33,023,210 Arix shares for $57,078,670 aggregate (~£1.43/share).
- Buyer: RTW Biotech Opportunities Operating Ltd, a subsidiary of RTW Biotech Opportunities Ltd.
- Transaction closed January 19, 2024; Acacia no longer owns any Arix shares.

## SEC filing metadata
- accession: 0000934549-24-000003
- form_type: 8-K
- ticker: ACTG
- cik: 0000934549
- company_name: ACACIA RESEARCH CORP
- filed_at: 2024-01-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/934549/000093454924000003/0000934549-24-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/934549/000093454924000003/actg-20240119.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000934549-24-000003
- JSON: https://secwatch.observer/filing/0000934549-24-000003.json
- Plain text: https://secwatch.observer/filing/0000934549-24-000003.txt

## Key facts
- M&A Transactions
  ACACIA RESEARCH CORP completed a disposition involving RTW Biotech Opportunities Operating Ltd for US$57,078,670.12 in aggregate (representing £1.43 per share at an exchange rate of 1.2087 USD/GBP) (closed 2024-01-19).
  - Action: disposition
  - Counterparty: RTW Biotech Opportunities Operating Ltd
  - Consideration: US$57,078,670.12 in aggregate (representing £1.43 per share at an exchange rate of 1.2087 USD/GBP)
  - Closing: 2024-01-19
  source text: On January 19, 2024, Acacia Research Corporation (the “Company”) completed the sale of its 33,023,210 shares of Arix Bioscience PLC (“Arix”) to RTW Biotech Opportunities Operating Ltd, a subsidiary of RTW Biotech Opportunities Limited, for US$57,078,670.12 in aggregate (representing £1.43 per share at an exchange rate of 1.2087 USD/GBP).
  evidence_url: https://www.sec.gov/Archives/edgar/data/934549/000093454924000003/0000934549-24-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.